Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

"Unusual" Cancers Following Pandemic; Triumph in TNBC; Clinical Trial Interrupted by Shortage.

2.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

3.

Combination of significant weight gain and late motherhood greatly increases risk of breast cancer, study finds

4.

Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.

5.

Study sets benchmark for treatment of advanced cervical cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot